Two, Buy

Two Buy Ratings, Two Very Different Price Tags for Helus Pharma

Published on 11/19/2026 at 06:40 | Editorial boerse-global.de
Canaccord raised its Helus Pharma target to $58, Lucid to $79 — both buy. The split shows efficacy and safety need separate readings.
Helus Pharma Inc. Illustration mit AI erstellt.

Canaccord Genuity's Tuesday hike to its price target on Helus Pharma drew the usual headlines, but the more telling detail sits a few days earlier: Lucid Capital had already reaffirmed its own buy call, at a markedly different number. Both houses like the stock. They just don't agree on what it is worth — and that gap is a better starting point than either target on its own.

Canaccord analyst Sumant Kulkarni, according to media reports, lifted his target to $58 from $42 while keeping his buy rating intact. The change, in other words, lives in the valuation and not in the direction of the recommendation. Lucid Capital had stayed at buy on Monday, raising its target to $79 from $52 and pointing to the APPROACH study readout. Same verdict, targets $21 apart. Anyone reading only the rating line misses that spread.

Efficacy and safety are separate questions

Helus Pharma reported positive Phase 3 results for HLP003 on Monday, testing the compound as an add-on treatment for major depression. At six weeks, improvement on the MADRS scale ran 7.6 points ahead of placebo, with statistical significance at p < 0.0001. The benefit held at the twelve-week mark as well, where the placebo-adjusted gap was 7.0 points, again with a p-value below 0.0001. That is a concrete efficacy finding under trial conditions.

What it does not do is settle the safety picture. Helus Pharma disclosed three treatment-related serious adverse events, one of them a suicide attempt, as Reuters reported. The company described HLP003 as generally well tolerated and said it had identified no new safety signals. Reuters also noted that investors, in Monday's selloff, focused chiefly on the safety concerns even as depressive symptoms improved significantly.

Here is the distinction that matters: an efficacy measure and a safety disclosure are not rival answers to the same question. Both belong in any valuation. A reader who reduces the study to its placebo gap leaves out half the news — and the safety concerns, in turn, do not erase the efficacy result.

Should investors sell immediately? Or is it worth buying Helus Pharma Inc.?

What a price target cannot show

Financial position belongs in the same ledger. Helus Pharma posted a net loss of $103.1 million for the second quarter of fiscal 2027, against $33.7 million a year earlier. That widening loss is its own piece of news for shareholders, though it says nothing about how to weight HLP003's clinical benefit.

Liquidity stood at $171.1 million as of September 30. That figure describes the balance sheet on that date; the quarterly loss is not a measure of cash burned over the same stretch. Neither number alone tells you how long the money lasts.

The likelier upside case for Helus Pharma would be additional detail that puts the serious events in context and lets the safety overhang fade. The company's statement that it saw no new safety signals sits alongside the disclosure of the events rather than replacing an assessment of them. Investors would want to know under what circumstances the events occurred and how their frequency differed between study arms. Should such detail soften the concerns, the symptom benefit would carry more weight in the valuation — and Canaccord's higher target offers a marker, since the firm already treated the efficacy data as grounds for a richer multiple.

The downside path does not require the efficacy finding to lose credibility. If further disclosures sharpen the safety worries, that could cap what investors will pay for the candidate even with the symptom advantage unchanged. A statistically robust gap to placebo and a cautious view of the shares are not mutually exclusive.

The next real test

More granular safety data from APPROACH — above all, how the serious events broke down across study groups — would tell investors more than another target built on the same efficacy result. Only by reading the symptom improvement and the serious events side by side does the durability of the bullish case for HLP003 become visible.

Yesterday's 4.3% decline in the stock is a reminder of how differently the same week can read from an analyst's desk and from the trading floor. For now, the higher target is less an answer than an invitation to keep the questions separate: the trial delivered a measurable efficacy finding, the safety disclosures still need their own reckoning, and the quarterly figures show a steeper loss. None of those facts becomes sharper because a price target moved.

Ad

Helus Pharma Inc. Stock: New Analysis - 19 November

Fresh Helus Pharma Inc. information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Helus Pharma Inc. analysis...

Disclaimer...
en | CA23256X4075 | TWO | boerse | 70534014 |